EloraTZP vs Retatrutide: What the Three Datasets Show
A Lilly slide shows 29% weight loss in 31 weeks with eloralintide plus tirzepatide. Only 3 of 12 had data, and it can’t be compared with retatrutide’s 28.3%.
-
-
Novo’s $1.4 Billion Bet on Oral Macrocycles: What a Deal Validates and What It Doesn’t
Novo signed with Orbis for up to $1.4bn on oral macrocycles. Against two 2026 approvals, what the deal establishes and what it does not.
-
Chemically Pure, Biologically Contaminated: What Endotoxin Testing Measures
Three 2026 recalls traced to one contaminated raw material show why chemical purity and biological contamination are different questions.
-
It Was Sold as Retatrutide. The Regulator’s Lab Found No Retatrutide at All
The TGA tested a vial sold as retatrutide after a hospitalisation: no retatrutide, and about eight times the semaglutide of registered products.
-
Flmodafinil and Fladrafinil on the 2026 WADA Prohibited List
WADA named flmodafinil and fladrafinil under class S6 in 2026. Why it adds examples rather than a new ban, and what it means for confirmatory analysis.
-
The Global Peptide Manufacturing Arms Race Has Begun
Samsung Biologics opened a CHF 1.46 billion tender for PolyPeptide on 15 September, with 55.65% of shares already committed. CordenPharma closed its AmbioPharm acquisition in August. The scarce asset is not synthesis, it is purification.
-
From Grey Market to $80 Billion TAM? Why Wall Street Is Suddenly Paying Attention to Peptides
An FT Lex column put potential US peptide sales near $80bn a year. Analysts quoted by Reuters put the market regulatory change would unlock at $2.2 to $3.3bn. Both are right, because they measure different things. The arithmetic behind each.
-
After Antibody-Drug Conjugates, Are Peptide-Drug Conjugates Next?
TwoStep Therapeutics cleared an IND for TS-104, a peptide-drug conjugate delivering MMAE through an integrin-binding peptide, alongside a $62.5m Series A. What PDCs change relative to antibody-drug conjugates, and what the public record does not yet say.
-
Semaglutide in Children Aged 6 to 11: What the STEP Young Phase 3 Trial Actually Found
Novo Nordisk reported that 40.4% of children aged 6 to 11 fell below the obesity threshold on semaglutide against 0% on placebo. What that figure measures, why it is a secondary endpoint, how paediatric BMI thresholds work, and what the announcement did not report.
-
BPC-157 Is Entering a Phase 1 Trial After Rotator Cuff Repair: What NCT07803250 Will Actually Test
A Phase 1 study of BPC-157 after arthroscopic rotator cuff repair was posted to ClinicalTrials.gov on 3 September 2026. It is not the first registered human study, it states no dose, and it registers one endpoint. A close reading of the record.
